Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
SOUTH SAN FRANCISCO, Calif. , Nov. 02, 2016 -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that Bill Lis, chief executive officer, will present at the Credit Suisse 24th Annual Healthcare Conference on Tuesday, November 8, at 1:00 p.m. Mountain Standard Time in Scottsdale, Ariz.
The presentation will be webcast live and available for replay from Portola's website at www.portola.com in the Investor Relations section.
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company is advancing three programs, including betrixaban, an oral, once-daily Factor Xa inhibitor; AndexXa™ (andexanet alfa), a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a Syk/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective Syk inhibitors for inflammatory conditions. For more information, visit www.portola.com and follow the Company on Twitter @Portola_Pharma.
Investor Contact: Ana Kapor Portola Pharmaceuticals [email protected] Media Contact: Julie Normart W2O Group [email protected]
